These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. Gallagher SJ; Gunatilake D; Beaumont KA; Sharp DM; Tiffen JC; Heinemann A; Weninger W; Haass NK; Wilmott JS; Madore J; Ferguson PM; Rizos H; Hersey P Int J Cancer; 2018 May; 142(9):1926-1937. PubMed ID: 29210065 [TBL] [Abstract][Full Text] [Related]
12. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells. Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432 [TBL] [Abstract][Full Text] [Related]
13. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374 [TBL] [Abstract][Full Text] [Related]
14. A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model. Bellmann L; Cappellano G; Schachtl-Riess JF; Prokopi A; Seretis A; Ortner D; Tripp CH; Brinckerhoff CE; Mullins DW; Stoitzner P Int J Cancer; 2020 Mar; 146(5):1409-1420. PubMed ID: 31702822 [TBL] [Abstract][Full Text] [Related]
15. Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors. Torres-Collado AX; Jazirehi AR Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29904021 [TBL] [Abstract][Full Text] [Related]
16. Combination Treatment with the BRAF Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573 [TBL] [Abstract][Full Text] [Related]
17. PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab. Jazirehi AR; Lim A; Dinh T Am J Cancer Res; 2016; 6(10):2117-2128. PubMed ID: 27822406 [TBL] [Abstract][Full Text] [Related]
18. Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma. Yeon M; Kim Y; Jung HS; Jeoung D Front Cell Dev Biol; 2020; 8():486. PubMed ID: 32626712 [TBL] [Abstract][Full Text] [Related]
19. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323 [TBL] [Abstract][Full Text] [Related]
20. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways. Sun X; Li J; Sun Y; Zhang Y; Dong L; Shen C; Yang L; Yang M; Li Y; Shen G; Tu Y; Tao J Oncotarget; 2016 Aug; 7(33):53558-53570. PubMed ID: 27448964 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]